 
June 5, 2008
Freezing HIV Med Prices for U.S. Agencies
Pharmaceutical companies Gilead Sciences Inc. and Boehringer-Ingelheim GmbH will stop price increases on HIV/AIDS medications for U.S. federal agencies, according to an AIDS Healthcare Foundation (AHF) June 3 announcement reported on Bloomberg.com (Bloomberg.com, 6/3).
Gilead—maker of Truvada—will halt price increases to three U.S. federal and state agencies through December 31, 2010. Boehringer will freeze prices on its drug Aptivus for state AIDS programs through May 1, 2009.
“We urge the other drug companies to follow [Boehringer’s] and Gilead’s lead and to freeze price increases that create an unnecessary burden on an already overburdened public health system and keep lifesaving drugs out of reach for those who need them,” said AHF president Michael Weinstein in a statement.
Scroll down to comment on this story.
Previous Comments:
comments 1 - 2 (of 2 total)
Laura Chorba, Friday Harbor, 2008-06-11 11:11:03
What about a possible price decrease? Would a 'freeze' also stop prices from going down?
Steve, , 2008-06-10 13:15:31
Interesting. I wonder if this means that they will increase their prices to people without insurance, and also to Medicare recipients in the doughnut hole, to maintain their profit margins? The retail prices of these drugs are outrageously high and beyond reach, even for most middle class people who are chronically ill.
comments 1 - 2 (of 2 total)
[Go to top]
|
